People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Carmine Therapeutics, Inc. | — | Pharma | Series A | $13.7M | $161.9M | 2022 |
| Asylia Therapeutics, Inc. | — | Biotechnology | Series A | $8.2M | $218.5M | 2021 |
Elan Ezickson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elan Ezickson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JOSEPH KEKST | 1 | 2 |
| Harvey Lodish | 1 | 2 |
| Jeno Gyuris | 1 | 2 |
| Lin Xiangqian | 1 | 1 |
| Donald Haut | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.